Summary

Market Overview
The Global Cloning and Mutagenesis Market is anticipated to expand from USD 3.11 billion in 2025 to USD 8.95 billion by 2031, reflecting a compound annual growth rate (CAGR) of 19.26%. This specialized biotechnology field centers on the intentional alteration of genetic material to either produce exact replicas of organisms, cells, or DNA (cloning) or to initiate targeted genomic modifications (mutagenesis). Growth in this sector is largely fueled by ongoing progress in genetic engineering, a rising need for personalized therapies, and increasing funding for basic biotech research spanning agricultural and industrial uses.
Venture capital funding within the U.S. bioscience sector, which underpins cloning and mutagenesis technologies, achieved $26 billion in 2024, as reported by the Biotechnology Innovation Organization (BIO). Despite this strong financial backing, the market faces considerable obstacles due to the intricate regulatory and ethical frameworks surrounding genetic manipulation, which require strict supervision and widespread public approval to ensure broader adoption.
Market Driver
A major catalyst for the Global Cloning and Mutagenesis Market is the rising use of sophisticated gene editing tools, which greatly improve the accuracy and speed of genetic alterations. Breakthroughs like the CRISPR-Cas system consistently enhance the capacity for precise genomic modifications, facilitating more focused therapeutic and research initiatives. By equipping scientists with robust methods for base editing, gene insertion, and gene knockout, these technological strides expedite both scientific exploration and practical application. Reflecting the substantial financial interest in these foundational technologies, Cure. noted that CRISPR Therapeutics declared an upsized $550 million convertible senior notes offering in March 2026, a move that will further drive innovation and the commercialization of gene editing solutions.
At the same time, the escalating need for customized therapeutics and personalized medicine heavily impacts the market, as it demands precise genetic adjustments suited to unique patient characteristics. Methods in cloning and mutagenesis are essential for producing these individualized therapies, playing a role in everything from engineering therapeutic cells to establishing disease models for medication testing. This strategy tailors healthcare interventions to a person's specific lifestyle, environmental, and genetic elements. The tangible results of this demand are evident; the Personalized Medicine Coalition reported to the FDA in May 2025 that 2024 saw the approval of 18 novel personalized medicines and six cell- and gene-based treatments for specific cancers and genetic disorders. Highlighting the robust nature of the associated biopharma industry, JPMorgan recorded $82.7 billion in announced biopharma licensing values during the first quarter of 2026.
Market Challenge
The elaborate regulatory and ethical frameworks surrounding genetic manipulation pose a major hurdle for the expansion of the Global Cloning and Mutagenesis Market. This complicated setting introduces considerable unpredictability for innovators, resulting in extended product development schedules and higher expenses related to maintaining compliance. Furthermore, differing regulatory interpretations and strict supervisory processes across various regions can obstruct global partnerships and delay market access, ultimately impeding the progress and commercial rollout of novel genetic tools.
This obstacle directly affects how quickly new products are approved and introduced to the market. For example, the Alliance for Regenerative Medicine indicated that the United States was on track to approve merely 4 to 5 cell and gene therapies in 2025. Despite continuous scientific breakthroughs in genetic engineering, this low volume of market introductions highlights the extent to which strict and lengthy regulatory procedures restrict the shift from laboratory research to commercial availability. Consequently, such a demanding landscape may discourage essential funding, decelerating the growth of vital applications in the cloning and mutagenesis industry.
Market Trends
The digitization and automation of laboratory operations are profoundly transforming the Global Cloning and Mutagenesis Market by improving data reliability and workflow efficiency. Incorporating cloud networks, sophisticated software, and robotics enables the accurate and consistent performance of intricate genetic procedures, thereby minimizing human mistakes and boosting processing capacity. This shift allows laboratories to manage greater sample sizes and more complex experimental structures, both of which are vital for synthetic biology and pharmaceutical discovery. Thermo Fisher Scientific Inc. highlighted this momentum in its January 29, 2026, earnings call for the fourth quarter of 2025, revealing a 13% revenue growth in its Life Science Solutions division, which supplies laboratory workflow instruments.
Another crucial trend is the advancement of seamless, high-throughput cloning techniques, which facilitate the swift and effective assembly of recombinant DNA without the tedious phases of conventional methods. These improvements empower scientists to rapidly produce numerous expression vectors and gene variants for simultaneous testing, hastening the overall trajectory of therapeutic innovation and research. By reducing technical delays, these optimized processes broaden the potential for sophisticated genetic engineering endeavors. Highlighting the need for these scalable biomanufacturing solutions, Sartorius AG reported in its February 3, 2026, preliminary data for 2025 that its Bioprocess Solutions Division experienced a 9.5% rise in sales revenue in constant currencies.

Key Market Players
* Agilent Technologies Inc.
* Eurofins Scientific SE
* Sartorius AG
* Collecta Inc.
* Codex DNA Inc.
* Lonza Group AG
* Charles River Laboratories International Inc.
* TransGene Biotech Co. Ltd.
* Takara Bio, Inc.
* Thermo Fisher Scientific Inc.

Report Scope
In this report, the Global Cloning & Mutagenesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

# Cloning & Mutagenesis Market, By Gene Type
* Standard
* Complex
# Cloning & Mutagenesis Market, By Product Type
* Cloning Kits
* Mutagenesis Kits
# Cloning & Mutagenesis Market, By Technique
* Topo PCR Cloning
* Blunt End Cloning
* Seamless Cloning
* Site-Directed Mutagenesis
* Others
# Cloning & Mutagenesis Market, By Application
* Gene Synthesis
* Gene Expression
* Gene Therapy
* Vaccine Research
* Others
# Cloning & Mutagenesis Market, By End User
* Pharmaceutical & Biotechnology Companies
* Academic & Research Institutions
* Others
# Cloning & Mutagenesis Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Cloning & Mutagenesis Market.
Available Customizations:
Global Cloning & Mutagenesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Cloning & Mutagenesis Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Gene Type (Standard, Complex)
5.2.2. By Product Type (Cloning Kits, Mutagenesis Kits)
5.2.3. By Technique (Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, Others)
5.2.4. By Application (Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others)
5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. North America Cloning & Mutagenesis Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Gene Type
6.2.2. By Product Type
6.2.3. By Technique
6.2.4. By Application
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Cloning & Mutagenesis Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Gene Type
6.3.1.2.2. By Product Type
6.3.1.2.3. By Technique
6.3.1.2.4. By Application
6.3.1.2.5. By End User
6.3.2. Canada Cloning & Mutagenesis Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Gene Type
6.3.2.2.2. By Product Type
6.3.2.2.3. By Technique
6.3.2.2.4. By Application
6.3.2.2.5. By End User
6.3.3. Mexico Cloning & Mutagenesis Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Gene Type
6.3.3.2.2. By Product Type
6.3.3.2.3. By Technique
6.3.3.2.4. By Application
6.3.3.2.5. By End User
7. Europe Cloning & Mutagenesis Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Gene Type
7.2.2. By Product Type
7.2.3. By Technique
7.2.4. By Application
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Cloning & Mutagenesis Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Gene Type
7.3.1.2.2. By Product Type
7.3.1.2.3. By Technique
7.3.1.2.4. By Application
7.3.1.2.5. By End User
7.3.2. France Cloning & Mutagenesis Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Gene Type
7.3.2.2.2. By Product Type
7.3.2.2.3. By Technique
7.3.2.2.4. By Application
7.3.2.2.5. By End User
7.3.3. United Kingdom Cloning & Mutagenesis Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Gene Type
7.3.3.2.2. By Product Type
7.3.3.2.3. By Technique
7.3.3.2.4. By Application
7.3.3.2.5. By End User
7.3.4. Italy Cloning & Mutagenesis Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Gene Type
7.3.4.2.2. By Product Type
7.3.4.2.3. By Technique
7.3.4.2.4. By Application
7.3.4.2.5. By End User
7.3.5. Spain Cloning & Mutagenesis Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Gene Type
7.3.5.2.2. By Product Type
7.3.5.2.3. By Technique
7.3.5.2.4. By Application
7.3.5.2.5. By End User
8. Asia Pacific Cloning & Mutagenesis Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Gene Type
8.2.2. By Product Type
8.2.3. By Technique
8.2.4. By Application
8.2.5. By End User
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Cloning & Mutagenesis Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Gene Type
8.3.1.2.2. By Product Type
8.3.1.2.3. By Technique
8.3.1.2.4. By Application
8.3.1.2.5. By End User
8.3.2. India Cloning & Mutagenesis Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Gene Type
8.3.2.2.2. By Product Type
8.3.2.2.3. By Technique
8.3.2.2.4. By Application
8.3.2.2.5. By End User
8.3.3. Japan Cloning & Mutagenesis Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Gene Type
8.3.3.2.2. By Product Type
8.3.3.2.3. By Technique
8.3.3.2.4. By Application
8.3.3.2.5. By End User
8.3.4. South Korea Cloning & Mutagenesis Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Gene Type
8.3.4.2.2. By Product Type
8.3.4.2.3. By Technique
8.3.4.2.4. By Application
8.3.4.2.5. By End User
8.3.5. Australia Cloning & Mutagenesis Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Gene Type
8.3.5.2.2. By Product Type
8.3.5.2.3. By Technique
8.3.5.2.4. By Application
8.3.5.2.5. By End User
9. Middle East & Africa Cloning & Mutagenesis Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Gene Type
9.2.2. By Product Type
9.2.3. By Technique
9.2.4. By Application
9.2.5. By End User
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Cloning & Mutagenesis Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Gene Type
9.3.1.2.2. By Product Type
9.3.1.2.3. By Technique
9.3.1.2.4. By Application
9.3.1.2.5. By End User
9.3.2. UAE Cloning & Mutagenesis Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Gene Type
9.3.2.2.2. By Product Type
9.3.2.2.3. By Technique
9.3.2.2.4. By Application
9.3.2.2.5. By End User
9.3.3. South Africa Cloning & Mutagenesis Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Gene Type
9.3.3.2.2. By Product Type
9.3.3.2.3. By Technique
9.3.3.2.4. By Application
9.3.3.2.5. By End User
10. South America Cloning & Mutagenesis Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Gene Type
10.2.2. By Product Type
10.2.3. By Technique
10.2.4. By Application
10.2.5. By End User
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Cloning & Mutagenesis Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Gene Type
10.3.1.2.2. By Product Type
10.3.1.2.3. By Technique
10.3.1.2.4. By Application
10.3.1.2.5. By End User
10.3.2. Colombia Cloning & Mutagenesis Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Gene Type
10.3.2.2.2. By Product Type
10.3.2.2.3. By Technique
10.3.2.2.4. By Application
10.3.2.2.5. By End User
10.3.3. Argentina Cloning & Mutagenesis Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Gene Type
10.3.3.2.2. By Product Type
10.3.3.2.3. By Technique
10.3.3.2.4. By Application
10.3.3.2.5. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Cloning & Mutagenesis Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Agilent Technologies Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Eurofins Scientific SE
15.3. Sartorius AG
15.4. Collecta Inc.
15.5. Codex DNA Inc.
15.6. Lonza Group AG
15.7. Charles River Laboratories International Inc.
15.8. TransGene Biotech Co. Ltd.
15.9. Takara Bio, Inc.
15.10. Thermo Fisher Scientific Inc.
16. Strategic Recommendations
17. About Us & Disclaimer